TFSA Investors: Turn $81,500 Into $300,000 With These 2 Tech Stocks

Given their solid financials, healthy growth prospects, and attractive valuations, these two tech stocks are excellent additions to your TFSA.

| More on:
grow money, wealth build

Image source: Getty Images

A Tax-Free Savings Account (TFSA) allows Canadian citizens to earn tax-free returns on a specified investment amount called the contribution room. For this year, the Canadian Revenue Agency (CRA) has set the contribution room at $6,000, with the cumulative amount standing at $81,500. If you invest this amount in stocks that deliver returns at a CAGR ((compounded annual growth rate) of over 18%, you can create a wealth of over $300,000 by 2030. Meanwhile, I believe the following two tech stocks have the potential to deliver these returns.

Nuvei

Nuvei (TSX:NVEI)(NASDAQ:NVEI) provides payment technology solutions to its clients across 200 markets while supporting 150 currencies and 570 alternative payment methods (APM). Supported by its disciplined investment in sustainable growth initiatives, the company has continued to drive its financials.

In the recently announced second quarter, its total volumes grew by 38% to US$30.1 billion, with e-commerce forming 87% of its total volume. Amid organic growth and strategic acquisitions, its revenue grew by 19% to US$211.3 million. When many of its peers struggled to become profitable, the company’s adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) and adjusted net income stood at US$184.4 million and $143.7 million, respectively. It generated a free cash flow of $163.3 million while having a cash balance of $721.6 million as of June 30.

Despite the challenging environment, Nuvei’s management has maintained its mid- to long-term guidance. The growth of e-commerce, geographical expansion, new APMs, and the growing legalization of online betting could boost the company’s growth in the coming years. Meanwhile, the management expects its volumes and revenue to grow over 30% in the medium term. Its adjusted EBITDA margin could cross 50% in the long run.

Despite its impressive financials and healthy growth prospects, Nuvei has lost close to 78% of its stock value compared to its 52-week high. Its NTM (next 12-month) price-to-earnings multiple has declined to 15.9, which is lower than its historical average. So, an investor has to invest $15.9 in the company to earn $1, which looks cheap considering the company’s growth potential. So, given its high-growth potential and attractive valuation, I expect the company to deliver multi-fold returns over the next eight years.

WELL Health Technologies

WELL Health Technologies (TSX:WELL), a digital healthcare company that provides end-to-end management tools for healthcare practitioners to provide virtual healthcare services, is my second pick. The company posted solid second-quarter earnings earlier this month, with its revenue growing by 127% to $140.3 million. Its organic growth stood at 20%, with substantial growth across its operating segments.

The company recorded 1.16 million patient visits during the quarter, representing an annualized rate of 4.66 million. Despite an inflationary environment, geopolitical tensions, and a challenging economic environment, the company posted an adjusted EPS (earnings per share) of $0.08 compared to a loss per share of $0.01 in the previous quarter. The expansion of its gross margins and revenue growth increased its adjusted EPS.

Buoyed by its impressive second-quarter performance and growing addressable market, WELL Health’s management has raised its 2022 revenue guidance from $525 million to $550 million. The increased adoption of virtual healthcare services, growing internet penetration, and technological advancement have expanded the company’s addressable market. Meanwhile, Fortune Business Insights project the global telehealthcare market to grow at a CAGR of over 30% through 2029.

Despite its impressive performance and high-growth prospects, WELL Health trades at an attractive NTM price-to-earnings multiple of 14.4, making it an attractive buy.

The Motley Fool has positions in and recommends Nuvei Corporation. Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

More on Tech Stocks

Bitcoin
Tech Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

These risky stocks can spike fast, but they can also implode if cash, debt, or demand turns against them.

Read more »

The virtual button with the letters AI in a circle hovering above a keyboard, about to be clicked by a cursor.
Tech Stocks

The AI Stocks That Could Dominate the TSX in 2026

Canadian tech stocks that have adopted and successfully integrated AI in their respective businesses could dominate the TSX in 2026.

Read more »

AI image of a face with chips
Tech Stocks

Is BlackBerry Stock Yesterday’s News?

BlackBerry is trying to reinvent itself as a critical software company, and the market may be slow to notice.

Read more »

The Meta Platforms logo displayed on a smartphone
Dividend Stocks

Billionaires Are Selling Meta Stock and Buying This TSX Stock Instead

Billionaire trimming is a clue to re-check fundamentals and valuation, not an automatic sell signal.

Read more »

man in suit looks at a computer with an anxious expression
Tech Stocks

Billionaires Are Dropping Tesla Stock and Buying This TSX Stock in Bulk

Billionaire selling can be a useful warning, but it isn’t automatically a reason to panic-sell.

Read more »

chip glows with a blue AI
Tech Stocks

This AI Stock is the Real Deal for Canadian Investors

The TSX’s AI king, a cash-generating machine beyond earnings, is the “real deal” for Canadian investors.

Read more »

AI image of a face with chips
Tech Stocks

2 Canadian AI Stocks Poised for Significant Gains

Add these two TSX AI-powered tech stocks to your self-directed investment portfolio to leverage market-beating returns.

Read more »

Circuit board with a microchips
Tech Stocks

Where Will Celestica Stock Be in 3 Years?

Celestica stock has returned a staggering 2,200% to shareholders in the last three years. Is there more upside for CLS…

Read more »